Enteric-coated mycophenolate sodium could be an alternative to methotrexate for GVHD prophylaxis.

Research output: Contribution to journalDebate/Note/Editorial

Abstract

Morbidity and mortality resulting from acute and subsequently chronic graft-versus-host disease (GVHD) pose a serious challenge to wider applicability of allogeneic stem cell transplantation (SCT). Mycophenolate mofetil (MMF) is a widely used drug in combination with a calcineurin inhibitor and often cyclosporine (CsA), in preventing GVHD. The use of MMF for acute GVHD (aGVHD) prophylaxis appears to result in significantly faster platelet engraftment and a lower incidence of severe mucositis compared to methotrexate, which could reduce the length of hospital stay. However, there is no statistically significant difference between MMF and methotrexate in regards to relapse risk, non-relapse mortality, or overall survival(1) . This article is protected by copyright. All rights reserved.

Details

Authors
  • Vladimir Lazarevic
Organisations
External organisations
  • Skåne University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology
Original languageEnglish
Pages (from-to)213-214
JournalEuropean Journal of Haematology
Volume97
Issue number3
Early online date2015 Dec 29
Publication statusPublished - 2016
Publication categoryResearch
Peer-reviewedYes